Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-08-29 | 2024-11-01 | 236261 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2020-11-26 | 2020-12-17 | 128933 |
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2018-01-22 | 2018-06-12 | 36817 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-10-04 | 2025-01-10 | 239373 |
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2025-01-30 | 2025-03-28 | 249074 |
| APO-GLIMEPIRIDE | 2MG | TABLET | Resolved | 2018-07-11 | 2019-09-21 | 55281 |
| APO-GLIMEPIRIDE | 4MG | TABLET | Resolved | 2017-11-28 | 2019-09-21 | 31007 |
| APO-GLIMEPIRIDE | 1MG | TABLET | Resolved | 2017-12-12 | 2019-09-21 | 32536 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-06-12 | 2022-07-28 | 162475 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-12-12 | 2025-01-17 | 245499 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2025-09-04 | 2025-09-12 | 266649 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214220 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-22 | 2022-08-06 | 165322 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-08 | 2024-01-12 | 212949 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2025-06-26 | 2025-07-04 | 261170 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-10-06 | 2024-01-12 | 206579 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-11 | 2022-08-12 | 164378 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2024-12-12 | 2025-01-17 | 245496 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-01-12 | 213559 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-11-06 | 2024-01-12 | 209339 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TIMOP | 0.5% | SOLUTION | Discontinued | 2019-01-03 | 2019-01-03 | 70894 |
| APO-TIMOP GEL | Discontinued | 2019-01-03 | 2019-01-03 | 71020 | ||
| APO-TIMOP OPH SOLN 0.25% | Discontinued | 2019-01-02 | 2019-01-02 | 70818 | ||
| APO-TOLTERODINE | 1MG | TABLET | Discontinued | 2018-09-08 | 2019-01-17 | 60822 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2019-06-12 | 60828 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2018-11-09 | 60825 |
| APO-TRAZODONE TABLETS 100MG | 100MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60831 |
| APO-TRAZODONE TABLETS 50MG | 50MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60834 |
| APO-VALACYCLOVIR | 500MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60840 |
| APO-VALGANCICLOVIR | 450MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60843 |
| APO-VALPROIC ACID ORAL SOLUTION | 250MG | SOLUTION | Discontinued | 2023-09-26 | 2023-11-02 | 205310 |
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71029 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71032 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71035 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71038 | ||
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Discontinued | 2019-01-03 | 2019-01-03 | 71054 |
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71044 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71048 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71051 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71057 |